Systematic review: Mortality associated with raised faecal immunochemical test and positive faecal occult blood results.
Journal
Alimentary pharmacology & therapeutics
ISSN: 1365-2036
Titre abrégé: Aliment Pharmacol Ther
Pays: England
ID NLM: 8707234
Informations de publication
Date de publication:
20 Aug 2024
20 Aug 2024
Historique:
revised:
22
04
2024
received:
25
03
2024
accepted:
31
07
2024
medline:
20
8
2024
pubmed:
20
8
2024
entrez:
20
8
2024
Statut:
aheadofprint
Résumé
Faecal haemoglobin (f-Hb) testing is used in colorectal cancer (CRC) screening and increasingly to guide the investigation in patients with symptoms suggestive of CRC. Studies have demonstrated increased mortality with raised f-Hb. To assess the association of raised f-Hb with all-cause, non-CRC (any cause excluding CRC) and cause-specific mortality. We searched Medline and Embase on 9 February 2024 to identify papers reporting mortality after faecal immunochemical (FIT) or guaiac faecal occult blood tests (gFOBT). The primary outcome was all-cause mortality following a positive compared to a negative test. The search identified 3155 papers. Ten met the inclusion criteria: three reported gFOBT and seven reported FIT results, as screening tests. These reported a total of 14,687,625 f-Hb results. Elevated f-Hb was associated with an increased risk of all-cause, non-CRC and cause-specific mortality including death from cardiovascular, digestive and respiratory diseases. Crude risk ratios for all-cause mortality with a positive versus negative test were derived from six papers (three reporting gFOBT, three FIT). An increased risk was demonstrated in five, with RRs ranging from 1.11 (95% CI: 1.06-1.16) to 2.95 (95% CI: 2.85-3.05). For non-CRC mortality risk, RRs ranged from 1.09 (95% CI: 1.04-1.15) to 2.79 (95% CI: 2.70-2.89). We did not perform meta-analysis due to a limited number of papers reporting suitable results for each type of f-Hb test. All-cause, non-CRC and cause-specific mortality appear higher in those with raised f-Hb. Population-based studies are warranted to elicit whether this association occurs in symptomatic patients.
Sections du résumé
BACKGROUND
BACKGROUND
Faecal haemoglobin (f-Hb) testing is used in colorectal cancer (CRC) screening and increasingly to guide the investigation in patients with symptoms suggestive of CRC. Studies have demonstrated increased mortality with raised f-Hb.
AIMS
OBJECTIVE
To assess the association of raised f-Hb with all-cause, non-CRC (any cause excluding CRC) and cause-specific mortality.
METHODS
METHODS
We searched Medline and Embase on 9 February 2024 to identify papers reporting mortality after faecal immunochemical (FIT) or guaiac faecal occult blood tests (gFOBT). The primary outcome was all-cause mortality following a positive compared to a negative test.
RESULTS
RESULTS
The search identified 3155 papers. Ten met the inclusion criteria: three reported gFOBT and seven reported FIT results, as screening tests. These reported a total of 14,687,625 f-Hb results. Elevated f-Hb was associated with an increased risk of all-cause, non-CRC and cause-specific mortality including death from cardiovascular, digestive and respiratory diseases. Crude risk ratios for all-cause mortality with a positive versus negative test were derived from six papers (three reporting gFOBT, three FIT). An increased risk was demonstrated in five, with RRs ranging from 1.11 (95% CI: 1.06-1.16) to 2.95 (95% CI: 2.85-3.05). For non-CRC mortality risk, RRs ranged from 1.09 (95% CI: 1.04-1.15) to 2.79 (95% CI: 2.70-2.89). We did not perform meta-analysis due to a limited number of papers reporting suitable results for each type of f-Hb test.
CONCLUSIONS
CONCLUSIONS
All-cause, non-CRC and cause-specific mortality appear higher in those with raised f-Hb. Population-based studies are warranted to elicit whether this association occurs in symptomatic patients.
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 The Author(s). Alimentary Pharmacology & Therapeutics published by John Wiley & Sons Ltd.
Références
Global, regional, and national burden of colorectal cancer and its risk factors, 1990‐2019: a systematic analysis for the global burden of disease study 2019. Lancet Gastroenterol Hepatol. 2022;7(7):627–647.
Westwood M, Lang S, Armstrong N, van Turenhout S, Cubiella J, Stirk L, et al. Faecal immunochemical tests (FIT) can help to rule out colorectal cancer in patients presenting in primary care with lower abdominal symptoms: a systematic review conducted to inform new NICE DG30 diagnostic guidance. BMC Med. 2017;15(1):189.
Excellence NIfHaC. Quantitative faecal immunochemical tests to guide referral for colorectal cancer in primary care. Diagnostics guidance [DG30]. National Institute for Health and Care Excellence 2017 https://www.nice.org.uk/guidance/dg30
Stonestreet J, Chandrapalan S, Woolley D, Uthman U, Arasaradnam RP. Systematic review and meta‐analysis: diagnostic accuracy of faecal immunochemical testing for haemoglobin (FIT) in detecting colorectal cancer for both symptomatic and screening population. Acta Gastroenterol Belg. 2019;82(2):291–299.
Pin‐Vieito N, Puga M, Fernández‐de‐Castro D, Cubiella J. Faecal immunochemical test outside colorectal cancer screening? World J Gastroenterol. 2021;27(38):6415–6429.
Monahan KJ, Davies MM, Abulafi M, Banerjea A, Nicholson BD, Arasaradnam R, et al. Faecal immunochemical testing (FIT) in patients with signs or symptoms of suspected colorectal cancer (CRC): a joint guideline from the Association of Coloproctology of Great Britain and Ireland (ACPGBI) and the British Society of Gastroenterology (BSG). Gut. 2022;71(10):1939–1962.
NICE. Quantitative faecal immunochemical testing to guide colorectal cancer pathway referral in primary care. Diagnostics guidance [DG56]. National Institute of Health and Care Excellence; 2023. https://www.nice.org.uk/guidance/DG56
Mousavinezhad M, Majdzadeh R, Akbari Sari A, Delavari A, Mohtasham F. The effectiveness of FOBT vs. FIT: a meta‐analysis on colorectal cancer screening test. Med J Islam Repub Iran. 2016;30:366.
Mole G, Withington J, Logan R. From FOBt to FIT: making it work for patients and populations. Clin Med (Lond). 2019;19:196–199.
Chen LS, Yen AM, Fraser CG, Chiu SY, Fann JC, Wang PE, et al. Impact of faecal haemoglobin concentration on colorectal cancer mortality and all‐cause death. BMJ Open. 2013;3(11):e003740.
Chen CH, Wen CP, Tsai MK. Fecal immunochemical test for colorectal cancer from a prospective cohort with 513,283 individuals: providing detailed number needed to scope (NNS) before colonoscopy. Medicine (Baltimore). 2016;95(36):e4414.
Lee YC, Li‐Sheng Chen S, Ming‐Fang Yen A, Yueh‐Hsia Chiu S, Ching‐Yuan Fann J, Chuang SL, et al. Association between colorectal Cancer mortality and gradient fecal hemoglobin concentration in colonoscopy noncompliers. J Natl Cancer Inst. 2017;109(5):djw269.
Juul JS, Hornung N, Andersen B, Laurberg S, Olesen F, Vedsted P. The value of using the faecal immunochemical test in general practice on patients presenting with non‐alarm symptoms of colorectal cancer. 2018.
Mowat C, Digby J, Strachan JA, Wilson R, Carey FA, Fraser CG, et al. Faecal haemoglobin and faecal calprotectin as indicators of bowel disease in patients presenting to primary care with bowel symptoms. Gut. 2016;65(9):1463–1469.
Jung Y, Im E, Lee J, Lee H, Moon C. Use of antiplatelet agents decreases the positive predictive value of fecal immunochemical tests for colorectal Cancer but does not affect their sensitivity. J Pers Med. 2021;11(6):497.
Clarke P, Jack F, Carey FA, Steele RJ. Medications with anticoagulant properties increase the likelihood of a negative colonoscopy in faecal occult blood test population screening. Color Dis. 2006;8(5):389–392.
Libby G, Barnett KN, Fraser CG, Steele RJC. Association between faecal occult bleeding and medicines prescribed for chronic disease: a data linkage study. J Clin Pathol. 2021;74(10):664–667.
Lee E, Lee GH, Park B, Ahn SS, Noh CK. Positive faecal immunochemical test predicts the onset of inflammatory bowel disease: a nationwide, propensity score‐matched study. Front Immunol. 2023;14:1128736.
Kim KW, Lee HJ, Han K, Moon JM, Hong SW, Kang EA, et al. Risk of diabetes in subjects with positive fecal immunochemical test: a Nationwide population‐based study. Endocrinol Metab. 2021;36(5):1069–1077.
Lee HJ, Han K, Soh H, Koh SJ, Im JP, Kim JS, et al. Occult blood in feces is associated with increased risk of psoriasis. Dermatology. 2022;238(3):571–578.
Noh CK, Lee E, Park B, Ahn SS. A positive faecal immunochemical test result and its association with the incidence of rheumatoid arthritis, systemic lupus erythematosus, and psoriatic arthritis: an analysis of one‐million national colorectal cancer screening programme results. BMC Med. 2022;20(1):226.
Chien K‐L, Lin T‐Y, Hsu C‐Y, Chan C‐C, Chen TH‐H, Chen L‐S. Association between faecal haemoglobin concentration and the risk of cardiovascular diseases among Taiwanese adults in a community‐based screening cohort. BMJ Open. 2020;10(6):e032633.
Libby G, Fraser CG, Carey FA, Brewster DH, Steele RJC. Occult blood in faeces is associated with all‐cause and non‐colorectal cancer mortality. Gut. 2018;67(12):2116–2123.
Kaalby L, Deding U, Al‐Najami I, Berg‐Beckhoff G, Bjørsum‐Meyer T, Laurberg T, et al. Faecal haemoglobin concentrations are associated with all‐cause mortality and cause of death in colorectal cancer screening. BMC Med. 2023;21(1):29.
Barnett KN, Clark GRC, Steele RJC, Fraser CG. Faecal Haemoglobin estimated by Faecal immunochemical tests—an indicator of systemic inflammation with real clinical potential. Diagnostics (Basel). 2021;11(11):2093.
Zhang YB, Pan XF, Chen J, Cao A, Xia L, Zhang Y, et al. Combined lifestyle factors, all‐cause mortality and cardiovascular disease: a systematic review and meta‐analysis of prospective cohort studies. J Epidemiol Community Health. 2021;75(1):92–99.
World Health Organization. Noncommunicable diseases 2022. Geneve, Switzerland: WHO Press. https://www.who.int/news‐room/fact‐sheets/detail/noncommunicable‐diseases
Moayyedi P, Achkar E. Does fecal occult blood testing really reduce mortality? A reanalysis of systematic review data. Am J Gastroenterol. 2006;101(2):380–384.
Page MJ, Mckenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA statement: an updated guideline for reporting systematic reviews. BMJ. 2020;2021:n71.
Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan—a web and mobile app for systematic reviews. Syst Rev. 2016;5(1):210.
Microsoft Corporation. Microsoft excel. 2016.
Wells G. The Newcastle‐Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta‐analyses. 2012 https://www.ohri.ca/programs/clinical_epidemiology/oxford.asp
Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;l4898:366.
StataCorp. Stata statistical software: release 18. College Station, TX: StataCorp LLC; 2023.
Whynes DK, Mangham CM, Balfour TW, Scholefield JH. Analysis of deaths occurring within the Nottingham trial of faecal occult blood screening for colorectal cancer. Gut. 2010;59(8):1088–1093.
Kaalby L, Al‐Najami I, Deding U, Berg‐Beckhoff G, Steele RJC, Kobaek‐Larsen M, et al. Cause of death, mortality and occult blood in colorectal Cancer screening. Cancers (Basel). 2022;14(1):246.
Moon JM, Lee HJ, Han K, Kim DH, Hong SW, Soh H, et al. Occult blood in feces is associated with an increased risk of ischemic stroke and myocardial infarction: a Nationwide population study. J Am Heart Assoc. 2021;10(1):e017783.
Jung YS, Lee J, Moon CM. Positive fecal immunochemical test results are associated with non‐colorectal cancer mortality. Korean J Intern Med. 2022;37(2):313–321.
Deding U, Kaalby L, Steele R, Al‐Najami I, Kobaek‐Larsen M, Plantener E, et al. Faecal haemoglobin concentration predicts all‐cause mortality. Eur J Cancer. 2023;184:21–29.
Wen CP, Tsai MK, Lee JH, Chiou HY, Wen C, Chu T‐WD, et al. Uncovering a dose‐response relationship between positive fecal immunochemical test (FIT) and all‐cause, cardiovascular and cancer‐related mortality. Eur J Intern Med. 2024;120:69–79.
Fraser CG, Allison JE, Halloran SP, Young GP. A proposal to standardize reporting units for fecal immunochemical tests for hemoglobin. J Natl Cancer Inst. 2012;104(11):810–814.
Benchimol EI, Smeeth L, Guttmann A, Harron K, Moher D, Petersen I, et al. The REporting of studies Conducted using Observational Routinely‐collected health Data (RECORD) statement. PLoS Med. 2015;12(10):e1001885.
Schmidt M, Schmidt SA, Sandegaard JL, Ehrenstein V, Pedersen L, Sørensen HT. The Danish National Patient Registry: a review of content, data quality, and research potential. Clin Epidemiol. 2015;7:449–490.
Amitay EL, Cuk K, Niedermaier T, Weigl K, Brenner H. Factors associated with false‐positive fecal immunochemical tests in a large German colorectal cancer screening study. Int J Cancer. 2019;144(10):2419–2427.
Centers for Disease Control and Prevention. Tobacco‐Related Mortality: Office on Smoking and Health, National Center for Chronic Disease Prevention and Health Promotion. 2020 https://www.cdc.gov/tobacco/data_statistics/fact_sheets/health_effects/tobacco_related_mortality/index.htm
Zorzi M, Battagello J, Selby K, Capodaglio G, Baracco S, Rizzato S, et al. Non‐compliance with colonoscopy after a positive faecal immunochemical test doubles the risk of dying from colorectal cancer. Gut. 2022;71:561–567.
Bhatia D, Sutradhar R, Paszat LF, Rabeneck L, Singh S, Tinmouth J, et al. Effect of chronic comorbidities on follow‐up colonoscopy after positive colorectal cancer screening results: a population‐based cohort study. Am J Gastroenterol. 2022;117(7):1137–1145.
Chiang C‐J, You S‐L, Chen C‐J, Yang Y‐W, Lo W‐C, Lai M‐S. Quality assessment and improvement of nationwide cancer registration system in Taiwan: a review. Jpn J Clin Oncol. 2015;45(3):291–296.
Silva IS. Cancer epidemiology: principles and methods. Lyon: International Agency for Research on Cancer; 1999.
Goungounga JA, Touraine C, Grafféo N, Giorgi R. Correcting for misclassification and selection effects in estimating net survival in clinical trials. BMC Med Res Methodol. 2019;19(1):10.
Wang L, Arnold K. Press release: misclassification of death may influence perceived value of Cancer screening. J Natl Cancer Inst. 2002;94(3):155.
Borenstein M, Hedges LV, Higgins JPT, Rothstein HR. A basic introduction to fixed‐effect and random‐effects models for meta‐analysis. Res Synth Methods. 2010;1(2):97–111.
Deeks JJ, Higgins JP, Altman DG, Group obotCSM. Analysing data and undertaking meta‐analyses. Cochrane Handbook for Systematic Reviews of Interventions; London: The Cochrane Collaboration. 2019. p. 241–284.
Menini S, Iacobini C, Vitale M, Pugliese G. The inflammasome in chronic complications of diabetes and related metabolic disorders. Cells. 2020;9(8):1812.
Greten FR, Grivennikov SI. Inflammation and cancer: triggers, mechanisms, and consequences. Immunity. 2019;51(1):27–41.
Henein MY, Vancheri S, Longo G, Vancheri F. The role of inflammation in cardiovascular disease. Int J Mol Sci. 2022;23(21):12906.
Proctor MJ, McMillan DC, Horgan PG, Fletcher CD, Talwar D, Morrison DS. Systemic inflammation predicts all‐cause mortality: a Glasgow inflammation outcome study. PLoS One. 2015;10(3):e0116206.
Tuomisto AE, Mäkinen MJ, Väyrynen JP. Systemic inflammation in colorectal cancer: underlying factors, effects, and prognostic significance. World J Gastroenterol. 2019;25(31):4383–4404.
Dregan A, Chowienczyk P, Molokhia M. Cardiovascular and type 2 diabetes morbidity and all‐cause mortality among diverse chronic inflammatory disorders. Heart. 2017;103(23):1867–1873.
Ku MS, Fann JC, Chiu SY, Chen HH, Hsu CY. Elucidating bidirectional relationship between metabolic syndrome and elevated faecal haemoglobin concentration: a Taiwanese community‐based cohort study. BMJ Open. 2019;9(3):e021153.
Nakajima K, Suwa K. Association between positive fecal occult blood test and diabetes in a population undergoing health screening. Clin Biochem. 2017;50(1–2):97–100.
Schrage B, Rübsamen N, Schulz A, Münzel T, Pfeiffer N, Wild PS, et al. Iron deficiency is a common disorder in general population and independently predicts all‐cause mortality: results from the Gutenberg health study. Clin Res Cardiol. 2020;109(11):1352–1357.
Stevens RG, Jones DY, Micozzi MS, Taylor PR. Body iron stores and the risk of cancer. N Engl J Med. 1988;319(16):1047–1052.
Sullivan JL. The iron paradigm of ischemic heart disease. Am Heart J. 1989;117(5):1177–1188.
Nieuwenburg SAV, Vuik FER, Kruip M, Kuipers EJ, Spaander MCW. Effect of anticoagulants and NSAIDs on accuracy of faecal immunochemical tests (FITs) in colorectal cancer screening: a systematic review and meta‐analysis. Gut. 2019;68(5):866–872.
Abulafi M, D'Souza N. The state of the faecal immunochemical test in symptomatic patients in the UK. Ann R Coll Surg Engl. 2022;104:1–3.
Cancer Research UK. Bowel cancer screening: primary care good practice guide. 2023.
Benziger CP, Roth GA, Moran AE. The global burden of disease study and the preventable burden of NCD. Glob Heart. 2016;11(4):393.
UNS Committee. UK National Screening Committee: screening in healthcare. 2022 https://www.gov.uk/guidance/principles‐of‐population‐screening/principles‐of‐screening